![]() NEW YORK, (GLOBE NEWSWIRE) - Ovid Therapeutics Inc. Transaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales. ![]() Ovid to invest $10 million in preferred equity in Graviton and will fund development programs.Development to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizures. ![]()
0 Comments
Leave a Reply. |